V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)

Inclusion Criteria: Healthy infant per investigator, 6 through 12 weeks of age Exclusion Criteria: History of congenital abdominal disorders, intussusception, or abdominal surgery Known or suspected impairment of immunological function Known hypersensitivity to any component of the rotavirus vaccine Prior administration of any rotavirus vaccine Known hypersensitivity or contraindication to any component of INFANRIX(tm) hexa Any infant born from a known HBsAg-positive mother Prior administration of any oral polio vaccine Receipt of one or more doses of inactivated poliovirus vaccine, diptheria, tetanus and acellular pertussis vaccine, diptheria, tetanus and pertussis vaccine, Haemophilus influenzae type b vaccine, or any hepatitis B vaccine prior to the first vaccination, or receipt of any vaccines with these antigens at any time during the course of the study Fever, with a rectal temperature greater than or equal to 38.1 degree C (greater than or equal to 100.5 degree F) at the time of immunization History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive Clinical evidence of active gastrointestinal illness Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination Infants residing in a household with an immunocompromised person Prior receipt of a blood transfusion or blood products Participation in another clinical study within 42 days before the beginning or anytime during the duration of the current clinical study Any infant who cannot be adequately followed for safety by a contact visit History of seizure disorders or prior history followed for safety by a contact visit Any condition that, in the opinion of the investigator, may interfere with the evaluation of the study objectives